



Press release
May 2, 2019
Gothenburg

XVIVO's patents for the heart preservation fluid approved in the US and Europe

XVIVO's patent for the heart preservation fluid has been approved in the US and Europe. Canada has already approved this patent. XVIVO has also previously received a patent for the heart evaluation equipment in Europe, Australia, Canada and China. The review of the patent application for the heart evaluation equipment is in its final stages in the US. Together these patents strengthen XVIVO's position in the heart transplantation field on all major markets in the world.

XVIVO has two main patents in the field of heart transplantation. The first of these covers the preservation fluid that is used in heart preservation and the other covers important parts of the evaluation equipment that is to be used for heart evaluation after preservation, but before transplantation. Patent applications have been submitted from both of these patent families recently.

These patents strengthens XVIVO's position in the field of heart transplantation. Patents are important in XVIVO's research-intensive business areas and not only entail a temporary monopoly situation for XVIVO's products, but can also be important in discussions with potential collaboration partners and to give XVIVO freedom in its further research and product development.

"It is positive that these patents have been approved on important markets in the world. This means that the company will continue to invest in products for both preservation and evaluation of the heart with even greater confidence," says Magnus Nilsson, CEO of XVIVO Perfusion.

May 2, 2019
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO

For further information, please contact
Christoffer Rosenblad, CFO, tel: +46 735 192159, email: christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, tel +46 31 788 2150, email: magnus.nilsson@xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The Xvivo share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69. E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on May 2, 2019.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.